Evidence map›Paper›PMID 35404472›Full record

SynthesisJournal of cellular physiology2022

Beneficial effects of melatonin on liver fibrosis: A systematic review of current biological evidence.

Beatriz San-Miguel, Paula Fernández-Palanca, José L Mauriz, María J Tuñón, Javier González-Gallego

Open access · hybridAbstract readSystematic Review
In one paragraph

Synthesis in Journal of cellular physiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Beatriz San-MiguelInstitute of Biomedicine, (IBIOMED), University of León, León, Spain.ORCID 0000-0002-4890-6309
Paula Fernández-PalancaInstitute of Biomedicine, (IBIOMED), University of León, León, Spain.ORCID 0000-0001-9765-9562
José L MaurizInstitute of Biomedicine, (IBIOMED), University of León, León, Spain.ORCID 0000-0003-3160-8599
María J TuñónInstitute of Biomedicine, (IBIOMED), University of León, León, Spain.ORCID 0000-0001-7827-5918
Javier González-GallegoInstitute of Biomedicine, (IBIOMED), University of León, León, Spain.ORCID 0000-0002-4386-9342
Instituto de Salud Carlos III · ES

Funding

CIBERehd is funded by Instituto de Salud Carlos III, Spain.Junta de Castilla y LeónMinisterio de Ciencia e Innovación
6 · The paper itself

Abstract

Hepatic fibrosis is a reversible response to either acute or chronic cellular injury from a wide variety of etiologies, characterized by excessive deposition of extracellular matrix resulting in liver dysfunction and cirrhosis. Melatonin (N-acetyl-5-methoxytryptamine), the main product secreted by the pineal gland, is a multitasking indolamine with important physiological functions such as anti-inflammatory and antioxidant actions, modulation of circadian rhythms, and immune system enhancement. Among the numerous biological activities of melatonin, its antifibrotic effects have received increasingly more attention. In this study, we performed a systematic review of publications of the last 10 years evaluating the mechanisms of action of melatonin against liver fibrosis. The study protocol was registered at PROSPERO (CRD42022304744). Literature research was performed employing PubMed, Scopus, and Web of Science (WOS) databases, and after screening, 29 articles were included. Results from the selected studies provided denoted the useful actions of melatonin on the development, progression, and evolution of liver fibrosis. Melatonin antifibrotic effects in the liver involved the reduction of profibrogenic markers and modulation of several cellular processes and molecular pathways, mainly acting as an antioxidant and anti-inflammatory agent. In addition, the indolamine influenced different molecular processes, such as hepatocyte apoptosis, modulation of autophagy and mitophagy, restoration of circadian rhythms, and modulation of microRNAs, among others. Although some limitations have been found regarding variability in the study design, the findings here summarized display the potential role of melatonin in ameliorating the development of liver fibrosis and its possible progression to liver cirrhosis and hepatocarcinoma.

Indexed as

Anti-Inflammatory AgentsAntioxidantsHumansLiver CirrhosisMelatoninAnti-Inflammatory AgentsAntioxidantsMelatoninantioxidantcirrhosishepatic fibrosisliver fibrosismelatonin

Identifiers

PMID35404472
PMCPMC9542733
OpenAlexW4223597977

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.